These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

878 related items for PubMed ID: 27549867

  • 1. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
    Shanshanwal SJ, Dhurat RS.
    Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
    [Abstract] [Full Text] [Related]

  • 2. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D.
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
    Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, Kawashima M, Manyak M, ARI114264 Study Group.
    J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
    [Abstract] [Full Text] [Related]

  • 4. Dutasteride in Androgenetic Alopecia: An Update.
    Arif T, Dorjay K, Adil M, Sami M.
    Curr Clin Pharmacol; 2017 Sep; 12(1):31-35. PubMed ID: 28294070
    [Abstract] [Full Text] [Related]

  • 5. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S, Lee YB, Choe SJ, Lee WS.
    Acta Derm Venereol; 2019 Jan 01; 99(1):12-17. PubMed ID: 30206635
    [Abstract] [Full Text] [Related]

  • 6. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
    Fertig RM, Gamret AC, Darwin E, Gaudi S.
    Dermatol Online J; 2017 Nov 11; 23(11):. PubMed ID: 29447628
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S.
    J Eur Acad Dermatol Venereol; 2018 Dec 11; 32(12):2257-2263. PubMed ID: 29972712
    [Abstract] [Full Text] [Related]

  • 8. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
    Kang HW, Chae MH, Park SH, Seo SP, Kim WT, Kim YJ, Yun SJ, Lee SC, Yoon TY, Kim WJ.
    J Urol; 2017 Dec 11; 198(6):1340-1345. PubMed ID: 28743526
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y.
    Clin Interv Aging; 2019 Dec 11; 14():399-406. PubMed ID: 30863034
    [Abstract] [Full Text] [Related]

  • 10. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
    Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS, Dutasteride Alopecia Research Team.
    J Am Acad Dermatol; 2006 Dec 11; 55(6):1014-23. PubMed ID: 17110217
    [Abstract] [Full Text] [Related]

  • 11. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
    Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH.
    Indian J Dermatol Venereol Leprol; 2014 Dec 11; 80(6):521-5. PubMed ID: 25382509
    [Abstract] [Full Text] [Related]

  • 12. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
    Gupta AK, Talukder M, Williams G.
    J Dermatolog Treat; 2022 Nov 11; 33(7):2946-2962. PubMed ID: 35920739
    [Abstract] [Full Text] [Related]

  • 13. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
    Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH.
    Int J Dermatol; 2014 Nov 11; 53(11):1351-7. PubMed ID: 24898559
    [Abstract] [Full Text] [Related]

  • 14. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E, Nole KL, Tosti A.
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec 11; 21(6):493-8. PubMed ID: 25268732
    [Abstract] [Full Text] [Related]

  • 15. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, Wollina U, Lotti T, Golubovic M, Binic I, Grabbe S, Goldust M.
    Dermatol Ther; 2020 May 11; 33(3):e13379. PubMed ID: 32279398
    [Abstract] [Full Text] [Related]

  • 16. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
    Iamsumang W, Leerunyakul K, Suchonwanit P.
    Drug Des Devel Ther; 2020 May 11; 14():951-959. PubMed ID: 32184564
    [Abstract] [Full Text] [Related]

  • 17. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
    Arias-Santiago S, Camacho-Martínez FM.
    Actas Dermosifiliogr; 2016 Nov 11; 107(9):709-711. PubMed ID: 27436801
    [No Abstract] [Full Text] [Related]

  • 18. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Andy G, John M, Mirna S, Rachita D, Michael K, Maja K, Aseem S, Zeljana B.
    Dermatol Ther; 2019 Mar 11; 32(2):e12647. PubMed ID: 30253001
    [Abstract] [Full Text] [Related]

  • 19. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women.
    Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD.
    J Investig Dermatol Symp Proc; 1999 Dec 11; 4(3):282-4. PubMed ID: 10674382
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.
    Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, Cho HK, Sim WY, Lew BL, Lee WS, Park HY, Hong SP, Ji JH.
    J Am Acad Dermatol; 2010 Aug 11; 63(2):252-8. PubMed ID: 20605255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.